PACTR202106822651688已完成4 期
Role of detection of lipoarabinomannan (LAM) in urine for diagnosis of pulmonary tuberculosis in HIV patients; Egyptian experience
asem hewidy0 个研究点目标入组 214 人开始时间: 2021年2月5日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 214
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •The study included seropositive HIV patients with a new diagnosis of either pulmonary or extra-pulmonary TB, and also included patients who were presented by symptoms suggestive for tuberculosis, changes in chest X ray that not improved by full course of antibiotics or positive tuberculin test = 5 mm.
排除标准
- •Patients on anti-TB drugs or negative screening for sero-positive HIV patients were excluded from the study.
研究者
相似试验
尚未招募
不适用
Detection of Lipoarabinomannan in Urine Evaluation of the STANDARDTMF TBLAMFIA and Its Impact on the Initial TB DiagnosisDiagnoses DiseaseTuberculosisNCT06306430Ospedale San Raffaele550
Unknown
不适用
Diagnostic Performance of a Novel Lipoarabinomannan.HIV Primary InfectionNCT05036694Médecins Sans Frontières, Kenya550
进行中（未招募）
不适用
Study to identify which changes in normal tissue could be related to long term adverse efects of radiotherapy associated to chemotherapy or to treatment with an antibody in patients with tumors of the head and neck regioocally advanced squamous head and neck cancerEUCTR2015-003012-21-ESGrupo Español de Tratamiento de Tumores de Cabeza y Cuello
进行中（未招募）
不适用
Applicability of a novel anti-lipoarabinomannan monoclonal antibody to detect Mycobacterium tuberculosis in formalin-fixed paraffin-embedded tissuelipoarabinomannanimmunohistochemistryAFBPCRTuberculosistuberculosisTCTR20190906001Ratchadapiseksompotch Fund, Faculty of Medicine120
已完成
不适用
MR based lipoprotein analysis for patients with advanced hypercholesterolemia or Lp(a)-hypercholesterolemia undergoing chronic lipoprotein apheresis or PCSK9-inhibitor therapyE78.0E78.5Pure hypercholesterolaemiaHyperlipidaemia, unspecifiedDRKS00012721Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education - BRAVE e.V.104